(Q37852801)

24 August 2017

1 reference

title

Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential (English)

1 reference

24 August 2017

0 references

1 reference

S Madsbad

2

0 references

Jens Juul Holst

series ordinal

3

object named as

J J Holst

1 reference

24 August 2017

Signe Sørensen Torekov

series ordinal

1

object named as

S S Torekov

1 reference

24 August 2017

publication date

15 March 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

12

1 reference

24 August 2017

issue

8

1 reference

24 August 2017

page(s)

593-601

1 reference

Global burden of obesity in 2005 and projections to 2030.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Central pre-proglucagon derived peptides: opportunities for treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Gastric distension induces c-Fos in medullary GLP-1/2-containing neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Glucagon-like peptide-1: a potent regulator of food intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Glucagon-like peptide-1 evokes action potentials and increases cytosolic Ca2+ in rat nodose ganglion neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Ghrelin attenuates the inhibitory effects of glucagon-like peptide-1 and peptide YY(3-36) on food intake and gastric emptying in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Transplantable rat glucagonomas cause acute onset of severe anorexia and adipsia despite highly elevated NPY mRNA levels in the hypothalamic arcuate nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Distal small bowel hormones: correlation with fasting antroduodenal motility and gastric emptying.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Plasma Enteroglucagon after Jejunoileal Bypass with 3:1 or 1:3 Jejunoileal Ratio

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Attenuated GLP-1 secretion in obesity: cause or consequence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7-36)amide secretion by circulating non-esterified fatty acids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Acute and long-term effects of metformin on the function and insulin secretory responsiveness of clonal β-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Liraglutide for weight loss in obese people

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Liraglutide for weight loss in obese people.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Medicare's search for effective obesity treatments: diets are not the answer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Pharmaceutical cost savings of treating obesity with weight loss medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Effects of lifestyle intervention on health care costs: Improving Control with Activity and Nutrition (ICAN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2011.00860.X

10.1111/J.1467-789X.2011.00860.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference